
ACTU Stock Forecast & Price Target
ACTU Analyst Ratings
Bulls say
Actuate Therapeutics has demonstrated significant progress in its clinical stage development, particularly with elraglusib, which has shown improved median overall survival and one-year survival rates in patients with metastatic pancreatic adenocarcinoma compared to standard treatment. The recent successful fundraising has strengthened the company’s balance sheet, providing the necessary financial flexibility to explore various regulatory pathways and manage critical operational costs associated with upcoming clinical studies. This combination of promising clinical data and enhanced financial position contributes to a positive outlook for the company's future development and potential market performance.
Bears say
Actuate Therapeutics Inc continues to face significant financial challenges, evidenced by its ongoing operational losses and reliance on external financing to fund its clinical development programs. The company's current cash reserves are insufficient to sustain its research activities over the long term, raising concerns about its ability to advance elraglusib through clinical trials. Additionally, the biopharmaceutical sector's competitive landscape, combined with the uncertainty surrounding clinical outcomes and regulatory approvals, contributes to a negative sentiment regarding Actuate Therapeutics's stock performance.
This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ACTU Analyst Forecast & Price Prediction
Start investing in ACTU
Order type
Buy in
Order amount
Est. shares
0 shares